Definitely not a pump, just bringing more attention to the company. Of course, now that results of Trimesta are imminent, everyone wants to keep an eye out. Place your bets! The very nice thing is there really is no big downside. IF results are not good, there is a whole lot else to look forward to. IF results are sub-par, stock will sink briefly, something good will be released on c-diff or one of the other indications, and boom, back in business. That said, I do not think results will be bad. You do not announce bad results at AAN, right? Right.
I fully agree with you it would be a strange and stupid thing to do for a renowned Rhonda Voskuhl, M.D., the lead investigator of the Phase II clinical trial evaluating the Company's oral estriol product candidate, Trimesta facing the audience of the American Academy of Neurology's in April and saying "I am sorry but the Trimesta drug is a complete failure " !!!!
The biography of this doctor is impressive.
I quote :
Dr. Voskuhl attended Phillips University in Enid, Oklahoma on full basketball and academic scholarships. She received her M.D. from Vanderbilt Medical School and completed neurology residency at the University of Texas Southwestern. Her fellowship years were spent in the Neuroimmunology Branch, NINDS, NIH. Dr. Voskuhl joined UCLA as Assistant Professor of Neurology in 1995, was promoted to Associated Professor in 2000 and Professor in 2004. She is Director of the UCLA MS Program. She received the Jack H. Skirball Endowed Chair in Multiple Sclerosis in 2006. She has received numerous grants from both the NIH and the National Multiple Sclerosis Society. Dr. Voskuhl’s laboratory is focused upon understanding the immunopathogenesis of multiple sclerosis (MS) through use of the murine model experimental autoimmune encephalomyelitis (EAE). She does basic science and also novel clinical trial design. She has studied the effect of sex hormones and sex chromosomes on both inflammation and neurodegeneration. This basic research has led to two novel pilot treatment trials in MS, as well as a multicenter trial at several sites in the U.S. In summary, Dr. Voskuhl’s research focus is to make basic discoveries at the research bench and to move them to novel therapies at the bedside, a prototypic example of translational research.
Her current titles include:
Jack H. Skirball Chair in Multiple Sclerosis Research
Director, UCLA Multiple Sclerosis Program
Professor of Neurology
David Geffen School of Medicine at UCLA